Wexford Capital’s Epizyme, Inc EPZM Stock Holding History

Wexford Capital’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,456	Closed	-$38K	–	394
2020 Q4	$38K	Buy	+3,456	New	+$42.6K	0.01%	275

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Wexford Capital's EPZM Position: Q1 2021 in Review

Wexford Capital sold out of Epizyme, Inc (EPZM) in Q1 2021, closing a stake of 3,456 shares — an estimated $38K sold.

Wexford Capital first reported a position in EPZM in Q4 2020 and held it in 1 quarter. The position peaked at $38K in Q4 2020. 137 funds tracked by Wall St. Rank hold EPZM as of Q1 2021.

Wexford Capital reported no remaining Epizyme, Inc position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 3,456 Epizyme, Inc shares in Q1 2021, an estimated $38K.
Wexford Capital first reported a position in Epizyme, Inc in Q4 2020 and held it in 1 quarter.
Wexford Capital's Epizyme, Inc position peaked at $38K in Q4 2020.
137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.